Fonar Corporation Reports 6% Revenue Increase and 37% EPS Growth in Q3 Fiscal 2025; Net Income Rises 25%

Reuters
05/15
Fonar Corporation Reports 6% Revenue Increase and 37% EPS Growth in Q3 Fiscal 2025; Net Income Rises 25%

Fonar Corporation announced its financial results for the third quarter of fiscal 2025, revealing a 6% increase in Total Revenues-Net to $27.2 million for the quarter ended March 31, 2025, compared to $25.7 million in the same quarter of the previous year. Net Income saw a notable rise of 25%, reaching $3.1 million for the quarter, up from $2.48 million the year before. Additionally, Diluted Net Income Per Common Share Available to Common Stockholders increased by 37% to $0.37 per share from $0.27 per share in the prior year's quarter. Income from Operations experienced a slight decrease of 2%, totaling $3.7 million compared to $3.8 million in the corresponding quarter of the previous year. The company also reported a decrease in Total Cash, Cash Equivalents, and Short-Term Investments by 4%, standing at $54.4 million as of March 31, 2025, down from $56.67 million as of June 30, 2024. Fonar's diagnostic imaging management subsidiary, Health Management Company of America $(HMCA.UK)$, set a new company record by completing 54,612 MRI scans in the third quarter, marking a 2.8% increase from the previous quarter and a 3.4% increase compared to the same quarter in fiscal 2024. Over the nine-month period, HMCA achieved a record 160,780 MRI scans, a 3.9% rise from 154,790 scans in the corresponding period of the previous year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fonar Corporation published the original content used to generate this news brief via Newsfile (Ref. ID: 252182) on May 15, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10